AI Engines For more Details: Perplexity Kagi Labs You
Osteoarthritis: Celecoxib is commonly prescribed for the management of osteoarthritis, a degenerative joint disease characterized by the breakdown of cartilage in the joints. It helps reduce pain, stiffness, and swelling associated with this condition, thereby improving mobility and quality of life.
Rheumatoid Arthritis: Celecoxib is also used in the treatment of rheumatoid arthritis, an autoimmune disease that causes inflammation of the joints. It helps alleviate symptoms such as joint pain, swelling, and stiffness, and may slow down the progression of the disease.
Ankylosing Spondylitis: Celecoxib is indicated for the symptomatic treatment of ankylosing spondylitis, a chronic inflammatory arthritis affecting the spine and large joints. It helps reduce pain and stiffness associated with this condition, improving flexibility and function.
Acute Pain: Celecoxib may be prescribed for the short-term relief of acute pain, such as that caused by dental procedures, surgery, or injury. It provides analgesic effects by inhibiting the production of inflammatory mediators in the body.
Menstrual Cramps: Celecoxib can be used to alleviate menstrual cramps (dysmenorrhea) by reducing prostaglandin levels in the uterus, which are responsible for causing uterine contractions and pain during menstruation.
Chronic Pain Syndromes: In some cases, celecoxib may be used off-label for the management of chronic pain syndromes such as fibromyalgia or chronic low back pain, particularly when other treatment options have been ineffective or poorly tolerated.
Colon Polyps: Celecoxib is approved for the prevention of colorectal polyps in patients with familial adenomatous polyposis (FAP), a rare inherited disorder characterized by the presence of multiple polyps in the colon and rectum. It helps reduce the number and size of polyps, potentially lowering the risk of colorectal cancer.
Cardiovascular Risk: Celecoxib, like other NSAIDs, is associated with an increased risk of cardiovascular events such as heart attack and stroke, especially when used at high doses or for prolonged periods. It is generally recommended to use the lowest effective dose for the shortest duration necessary, particularly in patients with pre-existing cardiovascular risk factors.
Gastrointestinal Effects: Celecoxib is associated with a lower risk of gastrointestinal ulcers and bleeding compared to traditional NSAIDs like ibuprofen or naproxen. However, it can still cause stomach upset, indigestion, and in rare cases, serious gastrointestinal complications such as perforation or bleeding.
Kidney Function: Prolonged use of celecoxib may impair kidney function and increase the risk of kidney damage or failure, particularly in individuals with pre-existing kidney disease or dehydration. It is important to stay well-hydrated and monitor kidney function regularly during treatment.
Allergic Reactions: Some individuals may experience allergic reactions to celecoxib, characterized by symptoms such as rash, itching, swelling of the face or throat, difficulty breathing, or severe skin reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis. If any of these symptoms occur, medical attention should be sought immediately.
Rank | Probiotic | Impact |
---|---|---|
species | Bacteroides uniformis | Reduces |
species | Faecalibacterium prausnitzii | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Odoribacter | genus | Decreases |
0 | 1 | Parabacteroides | genus | Decreases |
0 | 1 | Segatella | genus | Decreases |
0 | 1 | Phocaeicola | genus | Decreases |
0 | 1 | Clostridium | genus | Decreases |
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Butyricimonas | genus | Decreases |
0 | 2 | Bacteroides | genus | Decreases |
0 | 1 | Lacrimispora | genus | Decreases |
0 | 1 | Agathobacter | genus | Decreases |
0 | 1 | Coprobacter | genus | Decreases |
0 | 1 | Pseudobutyrivibrio | genus | Decreases |
0 | 1 | Coprococcus | genus | Decreases |
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Blautia | genus | Decreases |
0 | 1 | Clostridium perfringens A | no rank | Decreases |
0 | 1 | Clostridium perfringens B | no rank | Decreases |
0 | 1 | Clostridium perfringens C | no rank | Decreases |
0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
0 | 1 | Clostridium perfringens D | no rank | Decreases |
0 | 1 | Clostridium perfringens E | no rank | Decreases |
1 | 0 | Phocaeicola vulgatus | species | Decreases |
1 | 0 | Bacteroides ovatus | species | Decreases |
1 | 0 | Bacteroides xylanisolvens | species | Decreases |
1 | 0 | Odoribacter splanchnicus | species | Decreases |
1 | 0 | Parabacteroides distasonis | species | Decreases |
1 | 0 | Parabacteroides merdae | species | Decreases |
1 | 0 | Roseburia intestinalis | species | Decreases |
1 | 0 | Segatella copri | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
1 | 0 | Clostridium perfringens | species | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
1 | 0 | Lacrimispora saccharolytica | species | Decreases |
1 | 0 | Agathobacter rectalis | species | Decreases |
0 | 1 | Segatella bryantii | species | Decreases |
0 | 1 | Bacteroides sp. DH3716P | species | Decreases |
0 | 1 | Alistipes sp. dk3624 | species | Decreases |
0 | 1 | Bacteroides luhongzhouii | species | Decreases |
0 | 1 | Roseburia rectibacter | species | Decreases |
0 | 1 | Alistipes finegoldii | species | Decreases |
0 | 1 | Leyella stercorea | species | Decreases |
0 | 1 | Butyricimonas virosa | species | Decreases |
0 | 1 | Alistipes megaguti | species | Decreases |
1 | 0 | Coprococcus comes | species | Decreases |
0 | 1 | Prevotella intermedia | species | Decreases |
0 | 1 | Coprobacter fastidiosus | species | Decreases |
0 | 1 | Leyella lascolaii | species | Decreases |
0 | 1 | Bacteroides sp. D2 | species | Decreases |
0 | 1 | Coprobacter secundus | species | Decreases |
0 | 1 | Alistipes onderdonkii | species | Decreases |
0 | 1 | Butyricimonas faecalis | species | Decreases |
0 | 1 | Paraprevotella clara | species | Decreases |
0 | 1 | Prevotella bivia | species | Decreases |
0 | 1 | Faecalibacterium prausnitzii | species | Decreases |
0 | 1 | Bacteroides sp. M10 | species | Decreases |
0 | 1 | Parabacteroides johnsonii | species | Decreases |
0 | 1 | Alistipes shahii | species | Decreases |
0 | 1 | uncultured Alistipes sp. | species | Decreases |
0 | 1 | Alistipes senegalensis | species | Decreases |
0 | 1 | Bacteroides nordii | species | Decreases |
0 | 1 | Butyrivibrio crossotus | species | Decreases |
0 | 1 | Prevotella dentalis | species | Decreases |
2 | 0 | Bacteroides uniformis | species | Decreases |
1 | 0 | Streptococcus salivarius | species | Decreases |
1 | 0 | Blautia obeum | species | Decreases |
0 | 1 | Clostridium perfringens ATCC 13124 | strain | Decreases |
0 | 1 | Clostridium perfringens CP4 | strain | Decreases |
0 | 1 | Clostridium perfringens F262 | strain | Decreases |
0 | 1 | Clostridium perfringens JJC | strain | Decreases |
0 | 1 | Clostridium perfringens NCTC 8239 | strain | Decreases |
0 | 1 | Clostridium perfringens SM101 | strain | Decreases |
0 | 1 | Clostridium perfringens str. 13 | strain | Decreases |
0 | 1 | Clostridium perfringens WAL-14572 | strain | Decreases |
0 | 1 | Bacteroides uniformis ATCC 8492 | strain | Increases |
0 | 1 | Bacteroides uniformis CL03T00C23 | strain | Increases |
0 | 1 | Bacteroides uniformis CL03T12C37 | strain | Increases |
0 | 1 | Bacteroides uniformis dnLKV2 | strain | Increases |
0 | 1 | Bacteroides uniformis str. 3978 T3 i | strain | Increases |
0 | 1 | Bacteroides uniformis str. 3978 T3 ii | strain | Increases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
ADHD | 2.2 | 0.1 | 21 |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
Allergic Rhinitis (Hay Fever) | 0.7 | 0 | 0 |
Allergies | 1.2 | 1 | 0.2 |
Allergy to milk products | 0.3 | 0.5 | -0.67 |
Alopecia (Hair Loss) | 0.7 | 0.2 | 2.5 |
Alzheimer's disease | 2.6 | 2.9 | -0.12 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.2 | 1.2 | |
Ankylosing spondylitis | 1.4 | 0.1 | 13 |
Anorexia Nervosa | 0.6 | 2.1 | -2.5 |
Antiphospholipid syndrome (APS) | 1.2 | 0.2 | 5 |
Asthma | 2.3 | 0.7 | 2.29 |
Atherosclerosis | 0.9 | 1.9 | -1.11 |
Atrial fibrillation | 1.4 | 1.4 | 0 |
Autism | 4.4 | 4.6 | -0.05 |
Autoimmune Disease | 0 | 0.7 | 0 |
Barrett esophagus cancer | 0 | 0 | |
benign prostatic hyperplasia | 0.1 | -0.1 | |
Biofilm | 0 | 0 | |
Bipolar Disorder | 0.9 | 0.6 | 0.5 |
Brain Trauma | 0 | 0.7 | 0 |
Cancer (General) | 0.5 | 0.8 | -0.6 |
Carcinoma | 1 | 1 | 0 |
Celiac Disease | 2.5 | 1.2 | 1.08 |
Cerebral Palsy | 0.3 | 0.6 | -1 |
Chronic Fatigue Syndrome | 1.1 | 3.4 | -2.09 |
Chronic Kidney Disease | 0.5 | 1 | -1 |
Chronic Lyme | 0.6 | -0.6 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 0.8 | -3 |
Chronic Urticaria (Hives) | 0.2 | 1.3 | -5.5 |
Coagulation / Micro clot triggering bacteria | 0.5 | 0.7 | -0.4 |
Cognitive Function | 0.7 | 1.2 | -0.71 |
Colorectal Cancer | 3.5 | 1.2 | 1.92 |
Constipation | 0.8 | 0.5 | 0.6 |
Coronary artery disease | 0.2 | 2.1 | -9.5 |
COVID-19 | 4.4 | 5.3 | -0.2 |
Crohn's Disease | 3.9 | 2.6 | 0.5 |
Cushing's Syndrome (hypercortisolism) | 0.8 | -0.8 | |
cystic fibrosis | 0.6 | -0.6 | |
deep vein thrombosis | 0.6 | 0.7 | -0.17 |
Denture Wearers Oral Shifts | 0.1 | 0.1 | |
Depression | 4.3 | 3.9 | 0.1 |
Dermatomyositis | 0 | 0 | |
Eczema | 0.3 | 0.9 | -2 |
Endometriosis | 0.8 | 1 | -0.25 |
Eosinophilic Esophagitis | 0 | 0 | |
Epilepsy | 1.4 | 1.1 | 0.27 |
erectile dysfunction | 0.2 | 0.2 | |
Fibromyalgia | 1.8 | 1.1 | 0.64 |
Functional constipation / chronic idiopathic constipation | 4 | 2.9 | 0.38 |
gallstone disease (gsd) | 1.2 | 0.5 | 1.4 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.4 | 0.1 | 13 |
Generalized anxiety disorder | 0.2 | 0.3 | -0.5 |
giant cell arteritis | 0.2 | -0.2 | |
Glioblastoma | 0 | 0 | |
Gout | 0.7 | 0.2 | 2.5 |
Graves' disease | 0.5 | 0.9 | -0.8 |
Gulf War Syndrome | 0.3 | 1.1 | -2.67 |
Halitosis | 0.1 | 0 | 0 |
Hashimoto's thyroiditis | 1.2 | 0.2 | 5 |
Heart Failure | 0.8 | 1 | -0.25 |
hemorrhagic stroke | 0.4 | 0.4 | |
Hidradenitis Suppurativa | 0.1 | 0.1 | |
High Histamine/low DAO | 1.2 | 0.2 | 5 |
hypercholesterolemia (High Cholesterol) | 0.7 | 0.7 | |
hyperglycemia | 0.1 | 0.8 | -7 |
hypersomnia | 0 | 0 | |
hypertension (High Blood Pressure | 1.2 | 2.7 | -1.25 |
Hypothyroidism | 0.1 | 0.1 | 0 |
Hypoxia | 1.3 | 1.3 | |
IgA nephropathy (IgAN) | 0.5 | 2.7 | -4.4 |
Inflammatory Bowel Disease | 3.1 | 4.3 | -0.39 |
Insomnia | 0.3 | 0.9 | -2 |
Intelligence | 0.3 | 0.7 | -1.33 |
Intracranial aneurysms | 0.7 | 0.1 | 6 |
Irritable Bowel Syndrome | 1.9 | 3.1 | -0.63 |
ischemic stroke | 0.6 | 1 | -0.67 |
Liver Cirrhosis | 2.6 | 1.1 | 1.36 |
Long COVID | 2.7 | 2.7 | 0 |
Low bone mineral density | 0.6 | -0.6 | |
Lung Cancer | 0.4 | -0.4 | |
Lymphoma | 0.1 | -0.1 | |
Mast Cell Issues / mastitis | 0 | 0.1 | 0 |
ME/CFS with IBS | 0.2 | 0.4 | -1 |
ME/CFS without IBS | 0.2 | 0.7 | -2.5 |
membranous nephropathy | 0 | 0 | |
Menopause | 0.6 | 0.5 | 0.2 |
Metabolic Syndrome | 2.5 | 3.3 | -0.32 |
Mood Disorders | 4.2 | 2.8 | 0.5 |
multiple chemical sensitivity [MCS] | 0.1 | 0.1 | 0 |
Multiple Sclerosis | 2.2 | 4.2 | -0.91 |
Multiple system atrophy (MSA) | 0.1 | 0 | 0 |
myasthenia gravis | 0 | 0.7 | 0 |
neuropathic pain | 1.7 | -1.7 | |
Neuropathy (all types) | 0.1 | 1.8 | -17 |
neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.5 | 1.6 | 0.56 |
NonCeliac Gluten Sensitivity | 0.1 | 0.1 | 0 |
Obesity | 3.1 | 3.1 | 0 |
obsessive-compulsive disorder | 2.5 | 1.4 | 0.79 |
Osteoarthritis | 0.5 | 0.2 | 1.5 |
Osteoporosis | 0.7 | 0.1 | 6 |
pancreatic cancer | 0.5 | 0 | 0 |
Parkinson's Disease | 2.9 | 3.6 | -0.24 |
Polycystic ovary syndrome | 3.9 | 1.3 | 2 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | 0 |
Premenstrual dysphoric disorder | 0 | 0.4 | 0 |
primary biliary cholangitis | 0 | 0.2 | 0 |
Primary sclerosing cholangitis | 0.7 | 1.4 | -1 |
Psoriasis | 0.8 | 2.7 | -2.38 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.7 | 2.4 | -0.41 |
Rosacea | 0.8 | -0.8 | |
Schizophrenia | 1.8 | 1.2 | 0.5 |
scoliosis | 0.1 | 0.1 | |
Sjögren syndrome | 1.8 | 0.8 | 1.25 |
Sleep Apnea | 0.1 | 0.7 | -6 |
Slow gastric motility / Gastroparesis | 0.1 | 0.1 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
Stress / posttraumatic stress disorder | 1.2 | 1.2 | 0 |
Systemic Lupus Erythematosus | 1.9 | 1.5 | 0.27 |
Tic Disorder | 1.2 | 0.8 | 0.5 |
Tourette syndrome | 0 | 0.1 | 0 |
Type 1 Diabetes | 2.2 | 1.6 | 0.38 |
Type 2 Diabetes | 3.6 | 3.4 | 0.06 |
Ulcerative colitis | 2.9 | 5.2 | -0.79 |
Unhealthy Ageing | 1.4 | 2 | -0.43 |
Vitiligo | 1.1 | 0.9 | 0.22 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]